{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:28:10Z","timestamp":1783524490328,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1038\/sj.bjc.6602551","type":"journal-article","created":{"date-parts":[[2005,5,3]],"date-time":"2005-05-03T17:36:07Z","timestamp":1115141767000},"page":"1869-1876","source":"Crossref","is-referenced-by-count":127,"title":["Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration"],"prefix":"10.1038","volume":"92","author":[{"given":"A","family":"Wardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Barrett-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,5,3]]},"reference":[{"key":"BF6602551_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"BF6602551_CR2","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129\u2013138","journal-title":"Ann Acad Med Singapore"},{"key":"BF6602551_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"BF6602551_CR4","unstructured":"Department of Human Services (2003) Victoria's Hospital in the Home program. Victoria: State Government of Victoria"},{"key":"BF6602551_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","volume":"89","author":"SM Domchek","year":"2000","unstructured":"Domchek SM, Younger J, Finkelstein DM, Seiden MV (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89: 363\u2013368","journal-title":"Cancer"},{"key":"BF6602551_CR6","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038\u20132044","journal-title":"J Clin Oncol"},{"key":"BF6602551_CR7","first-page":"801","volume":"26","author":"SL Hughes","year":"1992","unstructured":"Hughes SL, Cummings J, Weaver F, Manheim L, Braun B, Conrad K (1992) A randomized trial of the cost effectiveness of VA hospital-based home care for the terminally ill. Health Serv Res 26: 801\u2013817","journal-title":"Health Serv Res"},{"issue":"Suppl 16","key":"BF6602551_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminoncol.2003.08.017","volume":"30","author":"L Lacerna","year":"2003","unstructured":"Lacerna L, Hohneker J (2003) Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 30 (Suppl 16): 150\u2013160","journal-title":"Semin Oncol"},{"key":"BF6602551_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082\u20131090","journal-title":"Cancer"},{"key":"BF6602551_CR10","volume-title":"Medicare's Post-acute Care Benefit: Background, Trends, and Issues to be Faced","author":"K Liu","year":"1999","unstructured":"Liu K, Gage B, Harvell J, Stevenson D, Brennan N (1999) Medicare's Post-acute Care Benefit: Background, Trends, and Issues to be Faced. Washington: US Department of Health and Human Services"},{"key":"BF6602551_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/intqhc\/14.4.285","volume":"14","author":"CR MacIntyre","year":"2002","unstructured":"MacIntyre CR, Ruth D, Ansari Z (2002) Hospital in the home is cost saving for appropriately selected patients: a comparison with in-hospital care. Int J Qual Health Care 14: 285\u2013293","journal-title":"Int J Qual Health Care"},{"key":"BF6602551_CR12","unstructured":"National Health Service (2000) The NHS Cancer Plan: A Plan for Investment, a Plan for Reform. London: Department of Health"},{"key":"BF6602551_CR13","unstructured":"National Institute for Clinical Excellence (2002) Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (Technology appraisal no. 48), ISBN 1-84257-233-4."},{"key":"BF6602551_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"BF6602551_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","volume":"49","author":"DM Parkin","year":"1999","unstructured":"Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33\u201364","journal-title":"CA Cancer J Clin"},{"key":"BF6602551_CR16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5694\/j.1326-5377.2000.tb125563.x","volume":"173","author":"D Rischin","year":"2000","unstructured":"Rischin D, White MA, Matthews JP, Toner GC, Watty K, Sulkowski AJ, Clarke JL, Buchanan L (2000) A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. Med J Aust 173: 125\u2013127","journal-title":"Med J Aust"},{"key":"BF6602551_CR17","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen B-L, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377\u2013387","journal-title":"Cancer J"},{"key":"BF6602551_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen B-L, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735\u20131744","journal-title":"Cancer"},{"key":"BF6602551_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan Jr W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen B-L, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100: 36\u201343","journal-title":"Cancer"},{"key":"BF6602551_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1136\/bmj.316.7147.1786","volume":"316","author":"S Shepperd","year":"1998","unstructured":"Shepperd S, Harwood D, Jenkinson C, Gray A, Vessey M, Morgan P (1998) Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes. BMJ 316: 1786\u20131791","journal-title":"BMJ"},{"key":"BF6602551_CR21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14: 2756\u20132768","journal-title":"J Clin Oncol"},{"key":"BF6602551_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gl\u00fcck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17: 846\u2013854","journal-title":"J Clin Oncol"},{"key":"BF6602551_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/030089168907500622","volume":"75","author":"V Ventafridda","year":"1989","unstructured":"Ventafridda V, De Conno F, Vigano A, Ripamonti C, Gallucci M, Gamba A (1989) Comparison of home and hospital care of advanced cancer patients. Tumori 75: 619\u2013625","journal-title":"Tumori"},{"key":"BF6602551_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/JCO.1986.4.10.1521","volume":"4","author":"V Vinciguerra","year":"1986","unstructured":"Vinciguerra V, Degnan TJ, Sciortino A, O\u2019Connell M, Moore T, Brody R, Budman D, Eng M, Carlton D (1986) A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients. J Clin Oncol 4: 1521\u20131528","journal-title":"J Clin Oncol"},{"key":"BF6602551_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42: 164\u2013175","journal-title":"Med Care"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602551","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:16:14Z","timestamp":1684412174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["BF6602551"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602551","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}